Premium
EUROPEAN TRAINING AND RESEARCH IN PERITONEAL DIALYSIS: SCIENTIFIC OBJECTIVES, TRAINING, IMPLEMENTATION AND IMPACT OF THE PROGRAMME
Author(s) -
Foster Tom L.,
Ferrantelli Evelina,
van Wiervan der Schaaf Tanja,
Beelen Robert H.J.
Publication year - 2014
Publication title -
journal of renal care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.381
H-Index - 27
eISSN - 1755-6686
pISSN - 1755-6678
DOI - 10.1002/jorc.12041
Subject(s) - medicine , peritoneal dialysis , renal replacement therapy , training (meteorology) , intensive care medicine , quality (philosophy) , outcome (game theory) , dialysis , quality of life (healthcare) , medical education , nursing , philosophy , physics , mathematics , mathematical economics , epistemology , meteorology
SUMMARY Background Peritoneal dialysis (PD) offers many advantages over hospital‐based haemodialysis, including better quality of life. Despite this, there is a general under‐utilisation of PD in Europe, which, to some extent, can be attributed to a lack of knowledge and education amongst renal clinicians and nurses. Objectives The specific aim of the European Training and Research in Peritoneal Dialysis (EuTRiPD) programme is to address this lack of knowledge, to develop a minimum of five biomarkers that allow the prediction of outcome in PD and three therapeutic treatments to improve outcome in PD. Approach EuTRiPD is a EU‐wide consortium with clinical, academic and commercial partners set up to address this knowledge gap. By training through research and close collaboration between academic and commercial entities we hope to improve the outcome and uptake of PD. It is the goal of EuTRiPD to improve the currently hampered diagnostic therapeutic developments in renal replacement therapy (RRT) and structure existing high‐quality PD‐related research across Europe. Conclusion It is hoped that EuTRiPD can and will have a significant impact on socio‐economic and scientific aspects of PD. It is the aim for EuTRiPD to boost the uptake of PD throughout Europe by making PD the obvious choice for patients.